On November 21, 2022 Starpharma (ASX: SPL, OTCQX: SPHRY) reported that VIRALEZE nasal spray has now launched online in Hong Kong and Macau, with launch in leading pharmacies to occur this week (Press release, Starpharma, NOV 21, 2022, View Source;mc_cid=d97ae29cc2&mc_eid=bf52dd3418 [SID1234624261]). This announcement follows the recently signed distribution agreement with Hengan Pharmacare Company Limited, a subsidiary of Hengan Group (HKSE:1044.HK) (see company announcement dated 21 October 2022).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For the Hong Kong and Macau markets, VIRALEZE will carry Hengan’s local brand which is also used for their COVID-19 related products, such as face masks and rapid antigen tests. The product will be supported with extensive traditional and digital marketing activities by Hengan Group.

Hengan Pharmacare Company Limited Managing Director Ms. Wong Pui Wai, Nancy commented, "We are excited to launch VIRALEZE in Hong Kong and Macau, bringing this innovative product to consumers."

Dr Jackie Fairley, Starpharma CEO, said "We are delighted to see our new partner, Hengan Group, launch VIRALEZE in Hong Kong and Macau so quickly and through leading pharmacies and online channels."